Funds holding NEUPHORIA THERAPEUTICS INC
ISIN US64136E1029 · United States
- Fund holders
- 7
- Of which ETFs
- 1 6 other funds
- Value held
- 2.1M $
- Share of capital
- 8.7 % of 5.4M shares on Sep 17, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| AdvisorShares Psychedelics ETF AdvisorShares Trust | 252,909 | 1.1M $ | 2.49 % | 4.67 % | as of Jun 30, 2026 ↗ |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 110,171 | 481.4K $ | 2.04 % | as of Jun 30, 2026 ↗ | |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 63,317 | 276.7K $ | 0.00 % | 1.17 % | as of Jun 30, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 31,546 | 167.5K $ | 0.00 % | 0.58 % | as of May 31, 2026 ↗ |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 8,036 | 42.7K $ | 0.15 % | as of May 31, 2026 ↗ | |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 2,427 | 12.9K $ | 0.04 % | as of May 31, 2026 ↗ | |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 2,001 | 10.6K $ | 0.04 % | as of May 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| AdvisorShares Psychedelics ETF AdvisorShares Trust | 2.49 % | as of Jun 30, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of May 31, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 0.00 % | as of Jun 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 7 | +1 | 470,407 | +73.9 % |
| 2026Q2 | 6 | 0 | 270,483 | +55.8 % |
| 2026Q1 | 6 | +3 | 173,635 | +123.7 % |
| 2025Q4 | 3 | +2 | 77,605 | +14.6 % |
| 2025Q3 | 1 | 0 | 67,733 | -2.8 % |
| 2025Q2 | 1 | 69,659 |
Institutional managers
19 managers declare this company to the SEC (Form 13F).
| Manager | Shares | Value | |
|---|---|---|---|
| Lynx1 Capital Management LP | 875,328 | 3.6M $ | as of Mar 31, 2026 |
| AdvisorShares Investments LLC | 155,367 | 632.3K $ | as of Mar 31, 2026 |
| Shay Capital LLC | 151,010 | 614.6K $ | as of Mar 31, 2026 |
| Balyasny Asset Management L.P. | 142,183 | 578.7K $ | as of Mar 31, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 98,516 | 401K $ | as of Mar 31, 2026 |
| Squadron Capital Management LLC | 76,728 | 312.3K $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 52,007 | 211.7K $ | as of Mar 31, 2026 |
| Ikarian Capital, LLC | 47,443 | 193.1K $ | as of Mar 31, 2026 |
| VANGUARD FIDUCIARY TRUST CO | 33,589 | 136.7K $ | as of Mar 31, 2026 |
| ADAR1 Capital Management, LLC | 30,000 | 122.1K $ | as of Mar 31, 2026 |
| FNY Investment Advisers, LLC | 26,500 | 107 $ | as of Mar 31, 2026 |
| CITADEL ADVISORS LLC | 19,331 | 78.7K $ | as of Mar 31, 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 14,000 | 57K $ | as of Mar 31, 2026 |
| Virtu Financial LLC | 12,033 | 49 $ | as of Mar 31, 2026 |
| COMMONWEALTH EQUITY SERVICES, LLC | 11,222 | 45.7K $ | as of Mar 31, 2026 |
| Merck & Co., Inc. | 10,027 | 40.8K $ | as of Mar 31, 2026 |
| UBS Group AG | 2,316 | 9.4K $ | as of Mar 31, 2026 |
| RHUMBLINE ADVISERS | 202 | 822 $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 58 | 236 $ | as of Mar 31, 2026 |
Declared shareholders of NEUPHORIA THERAPEUTICS INC
There is 1 beneficial ownership filing. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Coastlands Capital LP and 4 others | 4.23 % | 228,594 | as of Jul 23, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding NEUPHORIA THERAPEUTICS INC". https://titelia.com/en/stocks/neuphoria-therapeutics-inc-US64136E1029